Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Katarina Rydén‐Markinhuhta"'
Autor:
Hernán González‐King, Patricia G. Rodrigues, Tamsin Albery, Benyapa Tangruksa, Ramya Gurrapu, Andreia M. Silva, Gentian Musa, Dominika Kardasz, Kai Liu, Bengt Kull, Karin Åvall, Katarina Rydén‐Markinhuhta, Tania Incitti, Nitin Sharma, Cecilia Graneli, Hadi Valadi, Kasparas Petkevicius, Miguel Carracedo, Sandra Tejedor, Alena Ivanova, Sepideh Heydarkhan‐Hagvall, Phillipe Menasché, Jane Synnergren, Niek Dekker, Qing‐Dong Wang, Karin Jennbacken
Publikováno v:
Journal of Extracellular Vesicles, Vol 13, Iss 5, Pp n/a-n/a (2024)
Abstract Small extracellular vesicles (sEV) derived from various cell sources have been demonstrated to enhance cardiac function in preclinical models of myocardial infarction (MI). The aim of this study was to compare different sources of sEV for ca
Externí odkaz:
https://doaj.org/article/c768354e5bb04d27b8a38ee892355c5b
Publikováno v:
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 29:827-832
Dopaminergic agonists and NMDA-receptor antagonists form the basis for the dopamine and glutamate models of schizophrenia, respectively. In human subjects dopaminergic agonists evoke a psychosis resembling positive symptoms of schizophrenia, while NM
Publikováno v:
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 29:833-839
Schizophrenia is manifested by positive and negative symptoms, as well as cognitive deficits. Most existing antipsychotic agents have poor effects on the negative symptoms of schizophrenia, thus emphasizing the necessity for developing new antipsycho
Autor:
Katarina Rydén Markinhuhta, Clas Sonesson, Maria L. Carlsson, Maria Gullme, Fredrik Pettersson, Arvid Carlsson, Marie Nilsson
Publikováno v:
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 28:677-685
The Carlsson research group has developed a series of compounds capable of stabilising the dopamine system without inducing the deleterious hypodopaminergia that encumbers the currently used antipsychotic drugs. In the present study one of these dopa
Autor:
Daniel Kondziella, Katarina Rydén Markinhuhta, Eiliv Brenner, Ursula Sonnewald, Elvar M. Eyjolfsson, Maria L. Carlsson
Publikováno v:
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 31(9)
Schizophrenia-mimicking compounds such as phencyclidine (PCP) and MK801 are antagonists at the N-methyl-D-aspartate (NMDA) receptor and produce the whole spectrum of positive, negative, and cognitive symptoms. This is one of the most important pillar